Application of MUC13 as marker in early warning of bone metastasis of lung cancer

The invention relates to the technical field of biomedicine, and discloses application of MUC13 as a marker in early warning of lung cancer bone metastasis, and the enrichment level of the biomarker MUC13 is significantly up-regulated in serum of a patient with lung cancer bone metastasis. In addition, the bone metastasis-free survival time and the total survival time of the lung cancer patients with high MUC13 expression level are obviously shorter than those of the lung cancer patients with low MUC13 expression level. Therefore, MUC13 in serum can be regarded as a novel biological marker for early warning of the possibility of bone metastasis of lung cancer. 本发明涉及生物医学技术领域，公开了MUC13作为标志物在预警肺癌骨转移中的应用，所述生物标志物MUC13的富集水平在肺癌骨转移患者血清中显著上调。此外，MUC13表达水平较高的肺癌患者，其无骨转移生存时间和总生存时间显著短于MUC13表达较低的肺癌患者。因此，血清中的MUC13可被视为一种新型生物学标志物，用于预警肺癌骨转移的可能性。